← Human Trials & Peer-Reviewed Studies
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
Plain-language guide to PMID 19930006 (2009): double-blind randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 19930006
- Journal
- Diabetes, obesity & metabolism
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Jendle J et al. (9 authors)
- DOI
- 10.1111/j.1463-1326.2009.01158.x
- Registered trial
- NCT00294723, NCT00318461
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Liraglutide.
The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D).
Who Took Part
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.
The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.
Groups ran in parallel: each of the participants stayed in one arm throughout.
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured.
LEAD-2: adipose tissue area and hepatic steatosis were assessed.
What Was Measured
The subject headings attached to it are Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glycated Hemoglobin, Hypoglycemic Agents, Liraglutide and Sulfonylurea Compounds.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.